549 related articles for article (PubMed ID: 30768161)
1. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
[TBL] [Abstract][Full Text] [Related]
2. Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
Zullo A; Fiorini G; Scaccianoce G; Portincasa P; De Francesco V; Vassallo R; Urban F; Monica F; Mogavero G; Amato A; Vaira D
J Gastrointestin Liver Dis; 2019 Mar; 28(1):11-14. PubMed ID: 30851166
[TBL] [Abstract][Full Text] [Related]
3. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
[TBL] [Abstract][Full Text] [Related]
5. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
Liou JM; Chen PY; Luo JC; Lee JY; Chen CC; Fang YJ; Yang TH; Chang CY; Bair MJ; Chen MJ; Hsu YC; Hsu WF; Chang CC; Lin JT; Shun CT; El-Omar EM; Wu MS;
Gastroenterology; 2018 Oct; 155(4):1109-1119. PubMed ID: 29964036
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection.
Mestrovic A; Perkovic N; Bozic J; Pavicic Ivelja M; Vukovic J; Kardum G; Puljiz Z; Tonkic A
PLoS One; 2020; 15(12):e0244500. PubMed ID: 33378403
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial.
Zhang Y; Zhu YJ; Zhao Z; Zhao JT; Wang TY; Yang J; Chen DF; Lan CH
Eur J Gastroenterol Hepatol; 2020 May; 32(5):563-568. PubMed ID: 31851093
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.
Chuah SK; Hsu PI; Chang KC; Chiu YC; Wu KL; Chou YP; Hu ML; Tai WC; Chiu KW; Chiou SS; Wu DC; Hu TH
Helicobacter; 2012 Jun; 17(3):216-23. PubMed ID: 22515360
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
Chuah SK; Liang CM; Lee CH; Chiou SS; Chiu YC; Hu ML; Wu KL; Lu LS; Chou YP; Chang KC; Kuo CH; Kuo CM; Hu TH; Tai WC
Medicine (Baltimore); 2016 May; 95(19):e3586. PubMed ID: 27175657
[TBL] [Abstract][Full Text] [Related]
10. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
Tepeš B; Vujasinović M; Šeruga M; Stefanovič M; Forte A; Jeverica S
Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):676-83. PubMed ID: 26862930
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Zheng Q; Pan Y; Zhang L; Xiao SD
Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
[TBL] [Abstract][Full Text] [Related]
13. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
14. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication.
Tai WC; Liang CM; Lee CH; Chiu CH; Hu ML; Lu LS; Kuo YH; Kuo CM; Yen YH; Kuo CH; Chiou SS; Wu KL; Chiu YC; Hu TH; Chuah SK
Biomed Res Int; 2015; 2015():623732. PubMed ID: 26090428
[TBL] [Abstract][Full Text] [Related]
15. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment.
Luo L; Ji Y; Yu L; Huang Y; Liang X; Graham DY; Lu H
Dig Dis Sci; 2020 Dec; 65(12):3639-3646. PubMed ID: 32020360
[TBL] [Abstract][Full Text] [Related]
16. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
17. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication.
De Francesco V; Ridola L; Hassan C; Bellesia A; Alvaro D; Vaira D; Zullo A
J Gastrointestin Liver Dis; 2016 Jun; 25(2):147-50. PubMed ID: 27308644
[TBL] [Abstract][Full Text] [Related]
18. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
Puig I; González-Santiago JM; Molina-Infante J; Barrio J; Herranz MT; Algaba A; Castro M; Gisbert JP; Calvet X
Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
[TBL] [Abstract][Full Text] [Related]
19. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
20. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
